EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539

C Leland Rogers iD, Stephanie L Pugh, Michael A Vogelbaum, Arie Perry, Lynn S Ashby, Jignesh M Modi, Anthony M Alleman, Igor J Barani, Steve Braunstein, Joseph A Bovi, John F de Groot, Anthony C Whitton und 10 weitere

Neuro-Oncology · 05.01.2023 · 25 (1) · 137-145

DOI: 10.1093/neuonc/noac137 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 03.06.2022. Verfasst von C Leland Rogers und 21 weiteren Autor:innen. Beteiligte Einrichtung: GammaWest Cancer Services, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Three- and five-year progression-free survival (PFS) for low-risk meningioma managed with surgery and observation reportedly exceeds 90%. Herewith we summarize outcomes for low-risk meningioma patients enrolled on NRG/RTOG 0539.

Methods

This phase II trial allocated patients to one of three groups per World Health Organization grade, recurrence status, and resection extent. Low-risk patients had either gross total (GTR) or subtotal resection (STR) for a newly diagnosed grade 1 meningioma and were observed after surgery. The primary endpoint was 3-year PFS. Adverse events (AEs) were scored using Common Terminology Criteria for Adverse Events (CTCAE) version 3.

Results

Among 60 evaluable patients, the median follow-up was 9.1 years. The 3-, 5-, and 10-year rates were 91.4% (95% CI, 84.2 to 98.6), 89.4% (95% CI, 81.3 to 97.5), 85.0% (95% CI, 75.3 to 94.7) for PFS and 98.3% (95% CI, 94.9 to 100), 98.3%, (95% CI, 94.9 to 100), 93.8% (95% CI, 87.0 to 100) for overall survival (OS), respectively. With centrally confirmed GTR, 3/5/10y PFS and OS rates were 94.3/94.3/87.6% and 97.1/97.1/90.4%. With STR, 3/5/10y PFS rates were 83.1/72.7/72.7% and 10y OS 100%. Five patients reported one grade 3, four grade 2, and five grade 1 AEs. There were no grade 4 or 5 AEs.

Conclusions

These results prospectively validate high PFS and OS for low-risk meningioma managed surgically but raise questions regarding optimal management following STR, a subcohort that could potentially benefit from adjuvant therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsHumansRadiotherapy, AdjuvantProgression-Free SurvivalRiskRetrospective Studies

Stichwörter der Autor:innen

WHO grade 1 (benign)cooperative group trialmeningiomaobservationsurgery

Autor:innen und Institutionen

  • GammaWest Cancer Services, Salt Lake City, Utah, USA.
  • NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA.
  • Moffitt Cancer Center, Neuosurgery,Tampa, Florida, USA.
  • University of California, San Francisco, Neuropathology, San Francisco, California, USA.
  • Barrow Neurological Institute, Neurology, Phoenix, Arizona, USA.
  • MidState Medical Center, Radiology, Meriden, Connecticut, USA.

ORCID-Profile: C Leland Rogers

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Rogers, C. L., Pugh, S. L., Vogelbaum, M. A., Perry, A., Ashby, L. S., Modi, J. M., Alleman, A. M., Barani, I. J., Braunstein, S., Bovi, J. A., de Groot, J. F., Whitton, A. C., Lindhorst, S. M., Deb, N., Shrieve, D. C., Shu, H. K., Bloom, B., Machtay, M., Mishra, M. V., …, & Mehta, M. P. (2023). Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. Neuro-Oncology, 25(1), 137-145. https://doi.org/10.1093/neuonc/noac137

Vancouver

Rogers CL, Pugh SL, Vogelbaum MA, Perry A, Ashby LS, Modi JM, et al. Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. Neuro-Oncology. 2023;25(1):137-145. doi:10.1093/neuonc/noac137

BibTeX
@article{Rogers2023,
  author = {Rogers, C Leland and Pugh, Stephanie L and Vogelbaum, Michael A and Perry, Arie and Ashby, Lynn S and Modi, Jignesh M and Alleman, Anthony M and Barani, Igor J and Braunstein, Steve and Bovi, Joseph A and de Groot, John F and Whitton, Anthony C and Lindhorst, Scott M and Deb, Nimisha and Shrieve, Dennis C and Shu, Hui-Kuo and Bloom, Beatrice and Machtay, Mitchell and Mishra, Mark V and Robinson, Clifford G and Won, Minhee and Mehta, Minesh P},
  title = {Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {1},
  pages = {137--145},
  doi = {10.1093/neuonc/noac137}
}
Kostenlos starten →